Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010

Ann Rheum Dis. 2011 Mar;70 Suppl 1:i2-36. doi: 10.1136/ard.2010.146852.
No abstract available

Publication types

  • Consensus Development Conference

MeSH terms

  • Abatacept
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Monoclonal, Murine-Derived / therapeutic use
  • Antirheumatic Agents / therapeutic use*
  • Evidence-Based Medicine / methods
  • Humans
  • Immunoconjugates / therapeutic use
  • Immunologic Factors / therapeutic use*
  • Interleukin-1 / antagonists & inhibitors
  • Rheumatic Diseases / drug therapy*
  • Rituximab
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Monoclonal, Murine-Derived
  • Antirheumatic Agents
  • Immunoconjugates
  • Immunologic Factors
  • Interleukin-1
  • Tumor Necrosis Factor-alpha
  • Rituximab
  • Abatacept
  • tocilizumab